Life Sciences Collaboration Deals a Mainstay of Biotech Industry – Here Are the Tax Consequences

October.21.2022

In this Law360 article, partners Peter Connors and David Schulman, along with Michael Hirschfeld, a managing director at Andersen Tax LLC, provide guidance on the key tax considerations in play with Life Sciences Collaboration Deals.

The article is an in-depth analysis of what the authors describe as a mainstay of the biotech industry.

Read the full article here.

Authors

David Schulman Partner, Capital Markets, Mergers & Acquisitions

Washington, D.C.

See my bio

D:+1 202 339 8654
E: [email protected]

Practice:

Technology & Innovation Sector
Capital Markets
Mergers & Acquisitions
Technology Companies Group
Technology Transactions

vCard

See full bio

David Schulman Partner

Washington, D.C.

He provides strategic guidance on transactions involving mergers, acquisitions, collaborations, strategic alliances, licenses, capital markets, royalty and revenue-sharing and other financings for pharmaceutical and biotechnology companies and financial sponsors.

David is highly ranked for his life sciences work by Chambers USA and Chambers Global, with clients recognizing him as “one of the best business and corporate lawyers in the life sciences sector” with “a deep knowledge of the industry, which he successfully combines with great legal skills.” He has also been recognized by The Legal 500 and is listed as a “Life Sciences Star” in LMG Life Sciences.

Prior to joining Orrick, David was a partner with Dechert LLP, based in its Washington, D.C., and London offices and was a co-head of their Life Sciences practice. He is currently a member of the Board of Overseers of the School of Arts and Sciences of the University of Pennsylvania.